Clinsota
← Back to English Insights

Medical device regulatory insight · 2026-04-29

[Policy Interpretation] UK Clinical Trials Approved in as Fast as 7 Days

MHRA has now incorporated the Route B fast-track pathway into UK regulations, allowing low-risk clinical trial modifications to be approved in as little as 7 days. This article outlines the scope of applicability, fees, document checklist, and common risks.

[Policy Interpretation] UK Clinical Trials Approved in as Fast as 7 Days
On April 27, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a notice saying it would formally enshrine the "Route B fast track" in law. It took effect today (April 28, 2026).
I spent a full day reviewing the documents, asked two friends working on projects in the UK, and looked at the pilot data. In short: **it is indeed faster, but not every project can take this route**.
If you are conducting, or planning to conduct, a UK clinical trial—especially for medical devices—take five minutes to read this. I’m not going to give you boilerplate; I’ll only cover the practical points: **what qualifies, what does not, how much it costs, and what pitfalls to avoid**.

What exactly is Route B?

In the past, when you amended a clinical trial protocol in the UK, it went through a full review after submission, and results typically came back in 60-90 days.
Now there is another route — "Route B" — for low-risk amendments. For example:
    • Adjusting inclusion criteria
    • Updating the informed consent form version
    • Adding two investigators
After submission,MHRA has 14 days to stop it. **If they say nothing within 14 days, it is automatically approved**.
Pilot data (June - December 2025):
    • Average approval time:7 days
    • Automatic approval rate:89%
    • Stopped rate:11%(mainly due to incomplete materials)
So "as fast as 7 days" is real, but only if you submit a complete package in one go.

Which projects can use it? Which cannot?

Eligible (examples):
    • Changes to visit frequency (for example, from 3 visits to 5 visits)
    • Minor adjustments to the recruitment strategy (e.g., broadening the age range)
    • Changes in Ethics Committee membership
    • Wording refinements to the informed consent form
    • Updates to the data management plan
**Not eligible**：
    • Changes to the primary endpoint
    • Changes to device design or specifications
    • Adjustments to procedures related to subject safety
    • Major revisions to core parts of the protocol
**Class III medical devices** require particular caution. In a cardiovascular stent project we handled, broadening the enrollment criteria could proceed via Route B, but any adjustment to device parameters had to follow the conventional pathway.
Simple rule of thumb: **if a change affects subject safety or the device itself, it will almost certainly not qualify**.

Why is the UK introducing this now?

After Brexit, the UK needed to build its own regulatory framework to attract international trials. The 2023 UK Life Sciences Strategy white paper states this clearly: "to become the global destination of choice for clinical trials."
Timeline:
    • June 2025: Pilot launched
    • December 2025: Pilot concluded, with 147 amendment applications approved
    • 27 April 2026: Formally enacted
    • 28 April 2026: Took effect
Compared with other regions:
    • U.S. FDA: there is a Breakthrough Devices pathway, but the overall timeline remains long, averaging 12-18 months
    • European Union: CTIS provides a unified 60-day assessment, but the process is complex and often exceeds the timeline
    • Japan PMDA: Its early consultation mechanism is strong and suitable for innovative devices, but the documentation requirements are detailed
The UK's advantages are: **an English-speaking environment, strong IP protection, data accepted in both the U.S. and EUa long track record**.It is now using "speed" to win market share.

What is the true cost of running a UK project?

We calculated the actual expenditures for our three most recent projects (GBP):
**But there are two hidden costs that are easy to overlook**:
    1. **Upfront pre-submission review**: Have your internal team or a consultant review the dossier first to avoid an MHRA hold. We recommend budgeting £5,000-£10,000 for the pre-review.
    2. **Communication cost**: MHRA may raise questions, and you will need to respond within 24-48 hours. If your team is outside the UK, time-zone differences with the London office can be an issue, so it is best to have a local contact.

How can smaller companies control these costs?

  • The core process (submission and follow-up) can be outsourced, but ethics committee communication should be handled in-house as much as possible
  • Use our template checklist for self-assessment to save on consulting fees
  • Pay in stages: 30% upon proposal approval, 40% upon MHRA acceptance, and 30% after approval

What should you do if MHRA places the study on hold?

In the pilot, 11% were placed on hold, mainly for the following reasons:

    • Incomplete ethics documentation (40%)
    • Issues with the informed consent form (30%)
    • The SAE reporting process was not clearly described (20%)
    • Protocol deviations were not documented (10%)
**Response steps**:
    1. Hold an internal meeting within 24 hours to assign who will address each gap
    2. Submit the additional materials within 72 hours (if you delay too long, the MHRA may view it as a lack of engagement).
    3. If the MHRA has not responded within 15 days after the resubmission, proactively call to follow up.
    4. A 15-day grace period is generally granted.

For your own project, can it actually proceed via Route B?

I have compiled 5 questions for you to review first:

    1. **Does the change affect subject safety?** → No
    2. **Does it qualify as a low-risk modification?** (recruitment, informed consent, personnel) → Yes
    3. **Can all materials be submitted in full at one time?** → Yes
    4. **Has Ethics Committee approval already been obtained?** → Yes
    5. **Can you respond to MHRA questions within 14 days?** → Yes
If 4 or more criteria are met, you may consider Route B.
For a more detailed decision tree, refer to the original text.

Class III devices require particular caution.

**High-risk implantable devices** (stents, pacemakers, joints):
    • Amendments involving device design changes are generally not eligible for Route B.
    • However, changes such as adjusting visit frequency or relaxing enrollment criteria may be eligible.
**Class II devices** (monitors, ventilators, diagnostic reagents):
    • About 70% of amendments are eligible for Route B.
    • IVD reagents are particularly well suited.
**Software as a Medical Device (SaMD):**
    • Minor version iterations (for example, fine-tuning a detection algorithm) may proceed via Route B.
    • Major version updates or retraining a machine learning model may require re-approval.
**Companion diagnostics (CDx):**
    • For joint submissions, the MHRA must coordinate with the EMA.
    • It is advisable to begin discussions 6 months in advance

Let’s get practical: what do you need to prepare?

**Document checklist (must be submitted in one complete package)**:
    1. Ethics Committee approval documentation (version and date must match)
    2. Informed Consent Form (latest signed copy)
    3. SAE reporting procedure (clearly specify the 24-hour contact person)
    4. Protocol deviation log (for the most recent 3 months)
    5. Data Management Plan (including the data lock timeline)
    6. Investigator qualification documents (GCP certificates, CVs)
    7. Insurance certificate (clinical trial liability insurance)
    8. Medical device clinical trial filing documentation (if applicable)
**Submission platform**: CTIM (MHRA online system); select "Route B pathway" and retain the application reference number.
**14-day monitoring**: Log in daily whenever possible to check status. If a question is raised, respond within 24 hours.

What stage is your project at?

  1. Started, currently looking for a CRO
  2. In planning, evaluating the protocol
  3. Still observing, waiting a bit longer
  4. Not considering it, focused on the domestic market
If you're interested, click"Watching".

A few final remarks

The UK pathway has indeed become faster，But it is not a route available to everyone.**For Class III devices, projects involving safety considerations, or design changes, the process still needs to move at the necessary pace**.
To be candid: **the UK is not a universal solution. If your project is high-risk and involves design changes, you may still need to follow the traditional pathway**. We can help you save time and avoid unnecessary pitfalls.

#MedicalDevices#ClinicalTrials#CRO#GlobalMarketAccess#PolicyAnalysis